Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naive (TN) Mantle Cell Lymphoma (MCL)

被引：0

作者：

Lakhotia, Rahul ^{[1
]}

Pittaluga, Stefania ^{[1
]}

Phelan, James ^{[1
]}

Yang, Yandan ^{[1
]}

Davies-Hill, Theresa ^{[1
]}

Simard, Jillian ^{[1
]}

Muppidi, Jagan ^{[1
]}

Huang, Da Wei ^{[1
]}

Thomas, Craig ^{[2
]}

Ceribelli, Michele ^{[2
]}

Tosto, Frances ^{[2
]}

Pradhan, Amynah ^{[1
]}

Juanitez, Anna ^{[1
]}

Rimsza, Lisa ^{[3
]}

Jacob, Allison ^{[4
]}

Simmons, Heidi ^{[4
]}

Steinberg, Seth ^{[1
]}

Jaffe, Elaine ^{[1
]}

Staudt, Louis ^{[1
]}

Roschewski, Mark ^{[1
]}

Wilson, Wyndham ^{[1
]}

Melani, Christopher ^{[1
]}

机构：

[1] NCI, Bethesda, MD 20892 USA

[2] Natl Ctr Adv Translat Sci, Bethesda, MD USA

[3] Mayo Clin, Scottsdale, AZ USA

[4] Adapt Biotechnol, Seattle, WA USA

来源：

关键词：

MCL; VIPOR; targeted therapy in lymphoma; circulating tumor DNA; minimal residual disease;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MCL-349

引用

页码：S461 / S461

页数：1